Imperagen

Imperagen, established in 2021, operates out of Manchester, UK, specializing in enzyme engineering.Imperagen specializes in closed-loop, AI-guided enzyme engineering, offering advanced enzyme design services that utilize proprietary artificial intelligence models. The company focuses on optimizing enzyme performance for various applications, including pharmaceutical development, chemical synthesis, and consumer products. By leveraging high-throughput testing and physics-based simulations, Imperagen creates bespoke enzyme variants that meet specific industry requirements, significantly improving enzyme efficiency and reducing development cycles. Their services cater to diverse sectors, including biopharma, chemical manufacturing, and industrial biotechnology, serving clients who aim to enhance product performance, sustainability, and manufacturing efficiency.Imperagen generates revenue through B2B partnerships, providing enzyme optimization solutions to a variety of industrial clients. Transactions typically involve customized service agreements that encompass project onboarding, analytical method development, and iterative cycles of enzyme evolution. Clients engage with the company on a project basis, where they pay for specific enzyme optimization campaigns, which may last around four months and include up to 2,000 variants tested in high-throughput environments. The company's offerings facilitate advancements in enzyme performance, with revenue derived from the successful enhancement of biocatalysts and related applications in sectors such as pharmaceuticals and industrial processes. Future growth strategies include the launch of new enzyme products aimed at optimizing processes across various industries and expanding its reach into new markets, particularly in North America and Asia, by late 2026.

1. Seed

   Sep 17, 2025

   Amount

   $6.7M

   Investors

   Locked